Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 37 for:    Lanreotide | Neuroendocrine Tumors

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02288377
Recruitment Status : Completed
First Posted : November 11, 2014
Last Update Posted : March 30, 2020
Sponsor:
Information provided by (Responsible Party):
Federation Francophone de Cancerologie Digestive

Brief Summary:
This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine tumours.

Condition or disease Intervention/treatment Phase
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours Drug: lanreotide Drug: Placebo Phase 2 Phase 3

Detailed Description:

This is a European, prospective, multicentre, double-blind randomised study evaluating lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine tumours.

Depending on the phase II results, the study may be continued into phase III. The treatment and follow-up of patients will be the same in phase II and phase III.

After the first-line treatment, patients will be randomly assigned with a 1:1 ratio to receive either lanreotide or placebo. The study treatment should be initiated within 6 weeks following the confirmation date of stable disease or objective response.

Treatment period:

For each patient, the investigational products (lanreotide or placebo) will be provided according to a double-blind procedure until disease progression or toxicity, in accordance with the protocol.

The estimated average treatment duration for all patients is 12 months.

Follow-up period:

To evaluate overall survival, patients in phase II will have a minimum follow-up period of 12 months; if the study continues to phase III, these patients will have a maximum follow-up period of 10 years. Phase III patients will have a minimum follow-up period of 5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
Actual Study Start Date : January 2015
Actual Primary Completion Date : January 2020
Actual Study Completion Date : January 2020


Arm Intervention/treatment
Experimental: lanreotide
In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
Drug: lanreotide
Patients will receive lanreotide 120 mg every 28 days until disease progression

Placebo Comparator: placebo
In this arm, patients will receive placebo every 28 days until disease progression
Drug: Placebo



Primary Outcome Measures :
  1. Rate of patients alive and progression free at 6 months [ Time Frame: estimated 6 months after the last patient is randomized ]
    To evaluate the rate of patients alive and progression free at 6 months, assessed by the investigator according to RECIST criteria (version 1.1)


Secondary Outcome Measures :
  1. Rate of patients alive and progression free at 12 months [ Time Frame: estimated 12 months after the last patient is randomized ]
    To evaluate the rate of patients alive and progression free at 12 months, assessed by the investigator according to RECIST criteria (version 1.1)

  2. The toxicities [ Time Frame: estimated 6 months after the last patient is randomized ]
    Description using the NCI-CTC AE version 4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic (synchronous or metachronous) or locally advanced, non-resectable, well-differentiated duodeno-pancreatic neuroendocrine tumour, of grade 1 or 2 (WHO 2010 classification; Ki-67 ≤ 20%)
  • Progressive before first-line treatment
  • Histologically confirmed (either on primary tumour or metastases)
  • Pathological diagnosis validated by the NET consulting pathologist
  • Documented stable disease or objective response after first-line treatment, within 4 weeks (28 days) prior to randomisation
  • The first-line treatment will consist of either a chemotherapy or biotherapy (everolimus or sunitinib) as referred to TNCD or ENETS guidelines. Treatment must have been administered for 3 to 6 months for chemotherapy and for 6 months for biotherapy
  • Non-functional tumour or gastrinoma controlled by PPIs
  • Age > or = 18 years
  • WHO 0, 1 or 2
  • Effective contraception for male or female patients of childbearing age, defined as: oral contraceptives, intra-uterine devices, barrier contraceptive methods along with a spermicide gel, or surgical sterilisation. Female patients should use this contraception throughout the treatment period and for 6 months after the last treatment administration. Male patients should use contraception throughout the treatment period and for 3 months after the last treatment administration.
  • Signed informed consent prior to initiation of any study-specific procedures or treatment.

Exclusion Criteria:

  • History of haematological malignancy or other cancer, except those treated for more than 5 years and considered as cured, carcinoma in situ of the cervix and treated skin cancer (excluding melanoma)
  • Poorly differentiated neuroendocrine carcinoma or NET grade 3 ENETS (Ki-67 > 20%)
  • If primary resected, bone metastasis exclusively
  • Pre-treatment by somatostatin long-acting analogue
  • Total bilirubin ≥ 60 µmol/L
  • Uncontrolled diabetes
  • Contraindication to product used in the study or its components
  • Tumour arising in the context of a genetic disease
  • Pregnancy or lactation
  • Patients unable to undergo medical follow-up due to geographical, social, psychological or legal reasons
  • Concomitant participation in another clinical trial investigating a treatment during the treatment phase and within 30 days prior to the start of the study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02288377


Locations
Show Show 24 study locations
Sponsors and Collaborators
Federation Francophone de Cancerologie Digestive
Investigators
Layout table for investigator information
Principal Investigator: Come Lepage, Pr Federation Francophone de Cancerologie Digestive
Publications:
Layout table for additonal information
Responsible Party: Federation Francophone de Cancerologie Digestive
ClinicalTrials.gov Identifier: NCT02288377    
Other Study ID Numbers: PRODIGE31
First Posted: November 11, 2014    Key Record Dates
Last Update Posted: March 30, 2020
Last Verified: March 2020
Keywords provided by Federation Francophone de Cancerologie Digestive:
Lanreotide
Duodeno-pancreatic neuroendocrine tumours
Maintenance treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Lanreotide
Angiopeptin
Adenoma, Islet Cell
Adenoma
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents